Striatal Serotonin 4 Receptor is Increased in Experimental Parkinsonism and Dyskinesia-Reference-Cited by-同舟云学术

Striatal Serotonin 4 Receptor is Increased in Experimental Parkinsonism and Dyskinesia

Published:2024-02-03 Issue: Volume: Page:1-7
ISSN:1877-7171
Container-title:Journal of Parkinson's Disease
language:
Short-container-title:JPD

Author:

Cirillo Rossella¹²,Duperrier Sandra¹²,Parekh Pathik¹²³,Millot Mathilde¹²,Li Qin⁴,Thiolat Marie-Laure⁵⁶,Morelli Micaela³,Xie Jing¹⁷,Le Bars Didier⁸,Redouté Jérôme⁸,Bezard Erwan⁴⁵⁶,Sgambato Véronique¹²

Affiliation:

1. Institut des Sciences Cognitives Marc Jeannerod (ISCMJ), Unité Mixte de Recherche5229 du Centre National de la Recherche Scientifique (CNRS), Bron, France

2. Univ. de Lyon 1, Lyon, France

3. Department of Biomedical Sciences, Section of Neuroscience, Univ. of Cagliari, Monserrato, Italy

4. Motac Beijing Services, Beijing, China

5. Univ. de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France

6. CNRS, Institut desMaladies Neurodégénératives, Bordeaux, France

7. Institut du Vieillissement, Centrede Recherche Clinique Vieillissement Cerveau Fragilité, Hôpital des Charpennes, Villeurbanne, France

8. CERMEP-Imagerie du Vivant, Lyon, France

Abstract

Alterations of serotonin type 4 receptor levels are linked to mood disorders and cognitive deficits in several conditions. However, few studies have investigated 5-HT4R alterations in movement disorders. We wondered whether striatal 5-HT4R expression is altered in experimental parkinsonism. We used a brain bank tissue from a rat and a macaque model of Parkinson’s disease (PD). We then investigated its in vivo PET imaging regulation in a cohort of macaques. Dopaminergic depletion increases striatal 5-HT4R in the two models, further augmented after dyskinesia-inducing L-Dopa. Pending confirmation in PD patients, the 5-HT4R might offer a therapeutic target for dampening PD’s symptoms.

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Reference42 articles.

1. Initial clinical manifestations of Parkinson’s disease: Features and pathophysiological mechanisms;Rodriguez-Oroz;Lancet Neurol,2009

2. Serotonin transporter in Parkinson’s disease: A meta-analysis of positron emission tomography studies;Pagano;Ann Neurol,2017

3. The prominentrole of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease;Maillet;Brain,2016

4. The serotonergic system in Parkinson’s patients with dyskinesia: Evidence from imaging studies;Pagano;J Neural Transm,2018

5. Alterations of expression of the serotonin 5-HT4 receptor in brain disorders;Rebholz;Int J Mol Sci,2018